Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal <scp>BCRP</scp> and hepatic <scp>OATP1B1</scp> with minimal contribution from <scp>OATP1B3</scp>, <scp>NTCP</scp> and <scp>OAT3</scp>
Pharmacology research & perspectives